NO973679L - Eukaryotisk initieringsfaktor 5A (eIF-5A) mutanter - Google Patents

Eukaryotisk initieringsfaktor 5A (eIF-5A) mutanter

Info

Publication number
NO973679L
NO973679L NO973679A NO973679A NO973679L NO 973679 L NO973679 L NO 973679L NO 973679 A NO973679 A NO 973679A NO 973679 A NO973679 A NO 973679A NO 973679 L NO973679 L NO 973679L
Authority
NO
Norway
Prior art keywords
eif
mutants
initiation factor
eukaryotic initiation
rev function
Prior art date
Application number
NO973679A
Other languages
English (en)
Other versions
NO973679D0 (no
Inventor
Joachim Hauber
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9502771.0A external-priority patent/GB9502771D0/en
Priority claimed from GBGB9513505.9A external-priority patent/GB9513505D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO973679D0 publication Critical patent/NO973679D0/no
Publication of NO973679L publication Critical patent/NO973679L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

eIF-5A mutante proteiner som normalt er fri for betydelig eIF-5A akt:ivicet og som inhiberer Rev funksjon og således besitter en inhiberende fenotype med hensyn til Rev funksjon, og gener eller DNA eller cDNA sekvenser som koder derfor.
NO973679A 1995-02-13 1997-08-11 Eukaryotisk initieringsfaktor 5A (eIF-5A) mutanter NO973679L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502771.0A GB9502771D0 (en) 1995-02-13 1995-02-13 Organic compounds
GBGB9513505.9A GB9513505D0 (en) 1995-07-03 1995-07-03 Organic compounds
PCT/EP1996/000585 WO1996025492A1 (en) 1995-02-13 1996-02-12 EUKARYOTIC INITIATION FACTOR 5A (eIF-5A) MUTANTS

Publications (2)

Publication Number Publication Date
NO973679D0 NO973679D0 (no) 1997-08-11
NO973679L true NO973679L (no) 1997-10-13

Family

ID=26306494

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973679A NO973679L (no) 1995-02-13 1997-08-11 Eukaryotisk initieringsfaktor 5A (eIF-5A) mutanter

Country Status (15)

Country Link
EP (1) EP0811060A1 (no)
JP (1) JPH10509327A (no)
KR (1) KR19980702160A (no)
CN (1) CN1173897A (no)
AU (1) AU4665196A (no)
BR (1) BR9606951A (no)
CA (1) CA2210538A1 (no)
CZ (1) CZ255397A3 (no)
FI (1) FI972763A7 (no)
HU (1) HUP9801681A3 (no)
IL (1) IL117113A0 (no)
NO (1) NO973679L (no)
PL (1) PL321239A1 (no)
SK (1) SK109997A3 (no)
WO (1) WO1996025492A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001551A2 (en) * 1997-06-30 1999-01-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel inhibitor of cellular proliferation
US6867237B1 (en) * 2001-07-23 2005-03-15 Senesco Technologies, Inc. DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans
US7968523B2 (en) 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
US7166467B2 (en) 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
US7217517B2 (en) * 2001-07-23 2007-05-15 Senesco Technologies, Inc. Nucleic acids, polypeptides, and methods for modulating apoptosis
JP4754819B2 (ja) * 2002-05-07 2011-08-24 セネスコ テクノロジーズ，インコーポレイティド アポトーシス調節に関する核酸、ポリペプチド及び方法
NZ542665A (en) 2003-03-05 2008-05-30 Senesco Technologies Inc Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
EP1636364A2 (en) * 2003-06-06 2006-03-22 Senesco Technologies, Inc. INHIBITION OF APOPTOSIS-SPECIFIC ELF-5A ( EIF-5A1) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS
WO2009114487A2 (en) 2008-03-07 2009-09-17 Senesco Technologies, Inc. Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a desired polynucleotide
US8445638B2 (en) 2008-09-03 2013-05-21 Senesco Technologies, Inc. Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells

Also Published As

Publication number Publication date
HUP9801681A2 (hu) 1998-10-28
KR19980702160A (ko) 1998-07-15
BR9606951A (pt) 1997-10-28
MX9705757A (es) 1998-07-31
AU4665196A (en) 1996-09-04
IL117113A0 (en) 1996-06-18
SK109997A3 (en) 1998-04-08
FI972763L (fi) 1997-10-10
CZ255397A3 (cs) 1998-02-18
PL321239A1 (en) 1997-11-24
CA2210538A1 (en) 1996-08-22
CN1173897A (zh) 1998-02-18
FI972763A7 (fi) 1997-10-10
NO973679D0 (no) 1997-08-11
WO1996025492A1 (en) 1996-08-22
FI972763A0 (fi) 1997-06-26
HUP9801681A3 (en) 2000-10-30
EP0811060A1 (en) 1997-12-10
JPH10509327A (ja) 1998-09-14

Similar Documents

Publication Publication Date Title
MD430C2 (ro) Procedeu de obţinere a interferonelor leucocitare umane
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
BG102612A (en) Complementary adenoviral vector systems and cellular lines
IL117425A0 (en) Receptor activation by gas6
EP0662137B8 (en) Gene transcription and ionizing radiation: methods and compositions
SG141233A1 (en) Control of gene expression
WO1997035990A3 (en) Histone deacetylases, and uses related thereto
NO931955L (no) Reseptorer for leukemiinhiberende faktor
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
DE69434614D1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
AU3146597A (en) Non-nucleotide linking reagents
Exner et al. Posttranslational modification of Gαo1 generates Gαo3, an abundant G protein in brain
DK0698093T3 (da) Von Hippel-Lindau-(VHL)-sygdomsgen og tilsvarende cDNA og metoder til påvisning af bærere af VHL-sygdomsgenet
AU6724794A (en) GRB3-3 gene, its variants and their uses
IL159966A0 (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
DK0662134T3 (da) Polypeptider, der er involveret i biosyntesen af Streptogramin, nukleotidsekvenser, der koder for disse polypeptider, og deres anvendelse
EP0676469A3 (en) Transcription Factor APRF
SE9702338D0 (sv) An analytical method and industrial process including the same
AU669149B2 (en) Expression signal-peptide-free staphylokinases
HUP9801681A2 (hu) Mutáns proteinek
NO971378L (no) Cytokin betegnet LERK-6
DE60238333D1 (de) Auf antibiotikum basierendes genregulationssystem
WO2000012741A3 (fr) Systeme d'expression inductible
DE69526087D1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
DK0741791T3 (da) CD69-Tanskriptionsregulerende elementer